Author + information
- Received August 13, 2009
- Revision received September 29, 2009
- Accepted October 5, 2009
- Published online April 13, 2010.
- David Singh, MD,
- Eugenio Cingolani, MD,
- George A. Diamond, MD and
- Sanjay Kaul, MD⁎ ()
- ↵⁎Reprint requests and correspondence:
Dr. Sanjay Kaul, Division of Cardiology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048
Dronedarone is a new antiarrhythmic agent that was recently approved for the prevention of cardiovascular hospitalization driven by atrial fibrillation/flutter. Its approval was based largely on the results of the ATHENA (A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter) trial, which demonstrated a significant 24% reduction in the combined end point of all-cause mortality and cardiovascular hospitalization, primarily driven by the latter. However, several other clinical trials have evaluated the impact of dronedarone on various cardiovascular end points and yielded mixed results. In this article, we summarize the available evidence concerning dronedarone, and offer practical recommendations to health care providers regarding its use in the treatment of atrial fibrillation. We conclude that the available data support the use of dronedarone in select patient populations as a second- or third-line agent.
Dr. Diamond is on the Speakers' Panel of Merck.
- Received August 13, 2009.
- Revision received September 29, 2009.
- Accepted October 5, 2009.
- American College of Cardiology Foundation